-
Nothing about us, without us — establishing a patient and public involvement and engagement group Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-02-10 Rachel Horne, Rosemary Phillips, Mohammed A. Rauf
-
Moving towards meaningful patient and public engagement Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-02-10 Ruth Dobson, Charlotte Kenten, Joanna Brown, Clarissa Giebel, Sube Banerjee, Claudia Cooper
Patient and public involvement and engagement is increasingly mandated in funding applications, yet often remain tokenistic and transitory. Working with patient and public contributors requires investment, thought, care and time. We discuss approaches that aim to increase agency for coresearchers, with the goal of strengthening public confidence and trust in research.
-
The impact of rare genetic variants on Alzheimer disease Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-02-04 Lara De Deyn, Kristel Sleegers
-
Imperatives and co-benefits of research into climate change and neurological disease Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-01-20 Medine I. Gulcebi, Sara Leddy, Katherine Behl, Derk-Jan Dijk, Eve Marder, Mark Maslin, Anna Mavrogianni, Michael Tipton, David J. Werring, Sanjay M. Sisodiya
-
Markers help to predict dementia with Lewy bodies Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-01-17 Ian Fyfe
Biomarkers of Alzheimer disease (AD) pathology can predict the development of dementia with Lewy bodies (DLB) in people with idiopathic REM sleep behaviour disorder (iRBD), new research has shown. Levels of amyloid-β40 (Aβ40), Aβ42 and phosphorylated tau-181 (pTau181) were measured in blood from 142 people with iRBD. Among people who went on to develop DLB, the ratio of Aβ40 to Aβ42 was lower and the
-
MS drug beneficial in an underrepresented group Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-01-17 Ian Fyfe
Real-world data indicate that ocrelizumab is safe and effective in Latino people with multiple sclerosis (MS), according to a recent report. In a prospective observational study, a total of 305 people with relapsing–remitting MS, primary progressive MS or secondary progressive MS received ocrelizumab during a median follow-up period of 29.5 months. Only one person experienced a relapse, and disability
-
Exploring the long-term neurological consequences of COVID-19 Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-01-17 Heather Wood
Two recently published studies have provided new insights into the long-term effects of COVID-19 on the nervous system.
-
Neuron–tumour networks targeted Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-01-17 Ian Fyfe
Characterization of the networks formed between neurons and glioblastoma cells enables targeting of these networks with the potential to improve treatment, according to new research. Researchers used retrograde tracing with modified rabies virus to visualize neuron–tumour networks in patient-derived glioblastoma spheroid cultures, which revealed widespread connections. Surprisingly, the connections
-
Brain stimulation aids walking after spinal injury Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-01-17 Ian Fyfe
In a new study, deep brain stimulation (DBS) of the lateral hypothalamus facilitated recovery after spinal cord injury (SCI) in rodents and humans. The researchers identified glutamatergic neurons in the lateral hypothalamus as a therapeutic target from a brain atlas of neurons involved in recovery of walking. Stimulation of these neurons in mice and rats with SCI improved walking and led to a durable
-
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-01-15 Paolo A. Muraro, Alice Mariottini, Raffaella Greco, Joachim Burman, Ellen Iacobaeus, Matilde Inglese, John A. Snowden, Tobias Alexander, Maria Pia Amato, Lars Bø, Giacomo Boffa, Olga Ciccarelli, Jeffrey A. Cohen, Tobias Derfuss, Dominique Farge, Mark S. Freedman, Maria Gaughan, Christoph Heesen, Majid Kazmi, Kirill Kirzigov, Per Ljungman, Gianluigi Mancardi, Roland Martin, Varun Mehra, Lucia Moiola
-
Dementia is a neglected noncommunicable disease and leading cause of death Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-01-13 Lewis Arthurton, Paola Barbarino, Robert Anderson, Ben Schlaepfer, Nazak Salehi, Martin Knapp
Dementia is largely excluded from discussion of noncommunicable diseases, which limits its inclusion in health policies and allocation of resources — yet it is already a leading cause of mortality and its effects are set to increase. Alzheimer’s Disease International calls for changes in policies to address the effects of dementia now and in the future.
-
Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-01-10 Steven M. Greenberg, Francesco Bax, Susanne J. van Veluw
-
Sleep and circadian disturbances in children with neurodevelopmental disorders Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-01-08 Oliviero Bruni, Maria Breda, Valeria Mammarella, Maria Paola Mogavero, Raffaele Ferri
-
Inclusion in neurological research: empowering people living with neurological diseases Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-01-07 Maria Teresa Ferretti, Maria Bonaria Uccheddu, Richelle Flanagan, Iracema Leroi, Elena Moro
-
Alternating hemiplegia of childhood: challenges in a changing climate Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-01-07 Katherine Behl
Katherine Behl is a physician and the mother of a child with alternating hemiplegia of childhood (AHC) — an ultra-rare neurological disease that is exacerbated by temperature changes. Here, she highlights the day-to-day challenges of living with AHC and considers what stakeholders in climate action can learn from people with lived experience of disease.
-
Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis Nat. Rev. Neurol. (IF 28.2) Pub Date : 2025-01-02 Kiterie M. E. Faller, Helena Chaytow, Thomas H. Gillingwater
-
Immune mechanisms and shared immune targets in neurodegenerative diseases Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-12-16 Howard L. Weiner
-
Addressing disparities in neurology by enhancing inclusive practice Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-12-11 Lisa Kiani
Nature Reviews Neurology is interviewing individuals who are driving efforts to address disparities in neurology through a broad spectrum of diversity, equity and inclusion initiatives. We spoke with neuroimmunologist William L. Conte from the USA about his work to promote inclusive care for LGBTQ+ people with multiple sclerosis.
-
Exploring the role of sex hormones and gender diversity in multiple sclerosis Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-12-11 Cassie Nesbitt, Anneke Van Der Walt, Helmut Butzkueven, Ada S. Cheung, Vilija G. Jokubaitis
-
The global and regional burden of diabetic peripheral neuropathy Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-12-05 Masha G. Savelieff, Melissa A. Elafros, Vijay Viswanathan, Troels S. Jensen, David L. Bennett, Eva L. Feldman
-
Moving beyond immunoglobulin therapy for CIDP with efgartigimod Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-11-28 Jan D. Lünemann
The FDA recently approved efgartigimod for the treatment of chronic inflammatory demyelinating polyradiculopathy, providing an alternative to the immunoglobulin therapy that has been the standard treatment for years. The approval has the potential to improve access to treatment and outcomes, but many challenges remain in implementing trial findings into clinical practice.
-
α-Synuclein pathology as a target in neurodegenerative diseases Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-11-28 Hyejin Park, Tae-In Kam, Valina L. Dawson, Ted M. Dawson
-
Diets to promote healthy brain ageing Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-11-21 Sokratis Charisis, Mary Yannakoulia, Nikolaos Scarmeas
-
Intracerebral haemorrhage — mechanisms, diagnosis and prospects for treatment and prevention Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-11-15 David J. Seiffge, Simon Fandler-Höfler, Yang Du, Martina B. Goeldlin, Wilmar M. T. Jolink, Catharina J. M. Klijn, David J. Werring
-
Glymphatic dysfunction in PD clinical progression Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-11-13 Lisa Kiani
Risk of clinical milestones in Parkinson disease (PD) is associated with reduced glymphatic drainage, according to new research. The study of 175 people with PD showed that lower glymphatic function, measured by diffusion tensor imaging analysis of the perivascular space, was associated with increased risk of recurrent falls, wheelchair dependence and dementia. The study adds to growing evidence for
-
Dementia risk scores in diverse populations Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-11-13 Lisa Kiani
A recent analysis of dementia risk scores across diverse populations found that the validity of scores can differ between ethnic groups. The widely investigated Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) risk score, which estimates 20-year dementia risk at midlife on the basis of age, sex, education, systolic blood pressure, body mass index, cholesterol level and physical
-
High prevalence of hepatitis B in NMOSD Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-11-13 Lisa Kiani
A new study of a Taiwanese cohort found a high prevalence of resolved hepatitis B virus (HBV) infection in people with neuromyelitis optica spectrum disorder (NMOSD). Resolved HBV was found in 63.4% of people with NMOSD, compared with 16.4% in healthy controls, equating to a 5.7-fold increased risk of NMOSD following HBV infection. Furthermore, resolved HBV was associated with later onset of NMOSD
-
Immune responses influence sex differences in Alzheimer disease Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-11-13 Ian Fyfe
Sex differences in Alzheimer disease could be influenced by differences in immune responses, new research suggests.
-
Oligodendrocyte progenitor cell transplant for MS Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-11-13 Lisa Kiani
Transplantation of genetically modified oligodendrocyte progenitor cells (OPCs) into a mouse model of MS improves remyelination, new research has demonstrated. The researchers used CRISPR in human embryonic stem cell-derived OPCs to delete neuropilin 1, a receptor for SEMA3A that is highly expressed in demyelinated lesions in people with MS and is chemorepulsive to OPCs. Transplantation of the modified
-
Parkinson disease therapy: current strategies and future research priorities Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-11-04 Fabrizio Stocchi, Daniele Bravi, Aron Emmi, Angelo Antonini
-
The Digitized Memory Clinic Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-10-25 Mathias Holsey Gramkow, Gunhild Waldemar, Kristian Steen Frederiksen
-
BCAS1+ oligodendrocytes aid remyelination in MS Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-10-14 Heather Wood
A recent report has identified a population of brain-enriched myelin-associated protein 1 (BCAS1)-expressing oligodendrocytes in the cerebral cortex that seem to contribute to remyelination in multiple sclerosis (MS). Analysis of cortical tissue from patients in the early stages of MS and mouse models of demyelination revealed that BCAS1+ oligodendrocytes were abundant and adopted an activated, myelinating
-
Altered muscle cholesterol transport in ALS Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-10-14 Heather Wood
A paper recently published in Brain indicates that muscle cholesterol transport is dysregulated in amyotrophic lateral sclerosis (ALS). In skeletal muscle tissue biopsies from patients with ALS, the researchers found evidence of lysosomal cholesterol accumulation, which increased with disease severity and was associated with overexpression of the lysosomal cholesterol transporter genes NPC1 and NPC2
-
Engineered T cells show therapeutic potential for CNS injury Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-10-14 Lisa Kiani
A study in a mouse model of spinal cord injury helps to elucidate the neuroprotective mechanisms of autoimmune T cells during the early stages of injury, which could be harnessed through T cell therapy to improve long-term outcomes.
-
Evidence for an NMOSD prodrome Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-10-14 Heather Wood
Two new studies have produced evidence of a prodromal phase that precedes the clinical onset of neuromyelitis optica spectrum disorder (NMOSD). In the first study, Rotstein et al. reported an increase in health-care use by patients in the 5 years leading up to a clinical diagnosis of NMOSD, and in the second study, Lee et al. found that one in seven people with NMOSD presented with neurological symptoms
-
Lewy body pathology accelerates AD progression Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-10-14 Heather Wood
The presence of Lewy body (LB) pathology in addition to Alzheimer disease (AD) pathology is associated with acceleration of AD-related disease progression, according to new research. In a study involving 795 participants with mild cognitive impairment or dementia, individuals with AD+LB+ biomarker profiles in their cerebrospinal fluid showed more rapid cognitive decline and greater cortical hypometabolism
-
Coeliac disease as a model for understanding multiple sclerosis Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-10-08 Natalia Drosu, Kjetil Bjornevik, Marianna Cortese, Michael Levy, Ludvig M. Sollid
-
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-10-07 Lorraine V. Kalia, Angelica Asis, Nathalie Arbour, Amit Bar-Or, Riley Bove, Daniel G. Di Luca, Edward A. Fon, Susan Fox, Ziv Gan-Or, Jennifer L. Gommerman, Un Jung Kang, Eric C. Klawiter, Marcus Koch, Shannon Kolind, Anthony E. Lang, Karen K. Lee, Matthew R. Lincoln, Penny A. MacDonald, Martin J. McKeown, Tiago A. Mestre, Veronique E. Miron, Daniel Ontaneda, Maxime W. C. Rousseaux, Michael G. Schlossmacher
-
Systemic determinants of brain health in ageing Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-10-07 Eric E. Smith, Geert Jan Biessels, Virginia Gao, Rebecca F. Gottesman, Arthur Liesz, Neal S. Parikh, Costantino Iadecola
-
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-10-07 Dimos D. Mitsikostas, Alan Rapoport
Treatment options for migraine have expanded rapidly over the past few years. The latest success in a phase II trial of a new class of drugs for migraine holds the promise of another alternative, with important implications for our understanding of migraine and its clinical management.
-
Fluid biomarkers of chronic traumatic brain injury Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-10-03 Susanna Friberg, Caroline Lindblad, Frederick A. Zeiler, Henrik Zetterberg, Tobias Granberg, Per Svenningsson, Fredrik Piehl, Eric P. Thelin
-
Preparing for disease-modifying dementia therapies in the UK Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-09-17 Claudia Cooper, Charles R. Marshall, Jonathan M. Schott, Sube Banerjee
Although lecanemab has been licensed for use in the UK, the systems to deliver this or similar disease-modifying therapies do not exist. These systems need to be developed urgently, but not at the expense of post-diagnostic care.
-
NMOSD and MOGAD: an evolving disease spectrum Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-09-13 Akiyuki Uzawa, Frederike Cosima Oertel, Masahiro Mori, Friedemann Paul, Satoshi Kuwabara
-
Tau phosphorylation correlates with multiple sclerosis disease course Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-09-12 Heather Wood
New research adds to growing evidence of altered tau phosphorylation in multiple sclerosis.
-
Hijacked macrophages sustain glioblastoma cells Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-09-12 Ian Fyfe
Metabolic rewiring of a population of tumour-associated macrophages facilitates progression of glioblastoma, new research has revealed. A multi-omics approach demonstrated that the macrophages develop a lipid-laden phenotype, in which they accumulate cholesterol after uptake of myelin debris. Transfer of this accumulated cholesterol to glioblastoma cells helps to meet the high metabolic requirements
-
Free DNA activates secondary stroke mechanism Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-09-12 Ian Fyfe
After a stroke, circulating, cell-free DNA causes inflammasome activation in atherosclerotic plaques that can lead to recurrent stroke, work in a mouse model has shown. In a model of stroke-induced recurrent ischaemia, increased inflammation in plaques in the common carotid artery resulted from activation of the AIM2 inflammasome by cell-free DNA that primarily originated from neutrophil extracellular
-
Adaptive deep brain stimulation shows promise Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-09-12 Ian Fyfe
Adaptive deep brain stimulation (DBS) improves motor symptoms and quality of life in people with Parkinson disease compared with continuous DBS, the results of a pilot trial suggest. The study included four people with Parkinson disease, each of whom received continuous and adaptive DBS at different times to enable comparison of the effects. Adaptive stimulation was personalized according to motor
-
Blood profile indicates central inflammation in frontotemporal lobar degeneration Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-09-12 Ian Fyfe
A pro-inflammatory serum profile has been associated with frontotemporal lobar degeneration (FLTD) in new research, increasing the likelihood that blood-based biomarkers can be used for assessment of neuroinflammation in people with dementia. The researchers analysed cytokines in the serum of 214 people with syndromes associated with FTLD and 29 healthy individuals. Their analysis identified a profile
-
Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-09-10 Håkan Ashina, Rune H. Christensen, Debbie L. Hay, Amynah A. Pradhan, Jan Hoffmann, Dora Reglodi, Andrew F. Russo, Messoud Ashina
-
Assessing disease progression and treatment response in progressive multiple sclerosis Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-09-09 Giancarlo Comi, Gloria Dalla Costa, Bruno Stankoff, Hans-Peter Hartung, Per Soelberg Sørensen, Patrick Vermersch, Letizia Leocani
Progressive multiple sclerosis poses a considerable challenge in the evaluation of disease progression and treatment response owing to its multifaceted pathophysiology. Traditional clinical measures such as the Expanded Disability Status Scale are limited in capturing the full scope of disease and treatment effects. Advanced imaging techniques, including MRI and PET scans, have emerged as valuable
-
Stiff-person syndrome and related disorders — diagnosis, mechanisms and therapies Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-09-03 Marinos C. Dalakas
-
The influence of MOGAD on diagnosis of multiple sclerosis using MRI Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-09-03 Ruth Geraldes, Georgina Arrambide, Brenda Banwell, Àlex Rovira, Rosa Cortese, Hans Lassmann, Silvia Messina, Mara Assunta Rocca, Patrick Waters, Declan Chard, Claudio Gasperini, Yael Hacohen, Romina Mariano, Friedemann Paul, Gabriele C. DeLuca, Christian Enzinger, Ludwig Kappos, M. Isabel Leite, Jaume Sastre-Garriga, Tarek Yousry, Olga Ciccarelli, Massimo Filippi, Frederik Barkhof, Jacqueline Palace
-
Author Correction: Neurological care for LGBT+ people Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-08-22 Salvatore Giovanni Volpe, Joya Ahmad, Roshni Abee Patel, Nicole Rosendale
Correction to: Nature Reviews Neurology https://doi.org/10.1038/s41582-024-00944-0, published 18 March 2024.
-
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-08-19 Patricia Pozo-Rosich, Alicia Alpuente, Stephen D. Silberstein, Rami Burstein
-
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-08-12 Ian Fyfe
Antisense oligonucleotide treatment has therapeutic potential in a severe form of Charcot–Marie–Tooth disease, according to a new study.
-
Peripheral nervous system immune-related adverse events due to checkpoint inhibition Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-08-09 Meabh O’Hare, Amanda C. Guidon
-
Disentangling clinical and biological trajectories of neurodegenerative diseases Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-08-08 Nicolas Villain, Vincent Planche
-
Identifying and reducing risks of neurological complications associated with vaccination Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-08-07 Lahiru Handunnetthi, Maheshi N. Ramasamy, Lance Turtle, David P. J. Hunt
-
Single-cell atlas of Alzheimer disease vulnerability Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-08-06 Lisa Kiani
A single-cell transcriptomic atlas of six anatomical regions in the aged human brain with and without Alzheimer disease (AD) provides clues to cellular vulnerability to disease, a study in Nature reports. Various region-specific subtypes of excitatory and inhibitory neurons were reduced in brains from people with AD and shared elevated expression of genes in the reelin signalling pathway. In addition
-
Shared glial pathology in HD and schizophrenia Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-08-06 Lisa Kiani
A new study suggests that glial cells in both Huntington disease (HD) and schizophrenia share abnormal gene transcription patterns. RNA sequencing of glial progenitor cells derived from human pluripotent stem cells revealed preserved gene sets between the diseases that were distinct from healthy control donors. A large proportion of genes that were supressed in both diseases are involved in synaptic